Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Other Non-Current Liabilities: 2015-2025

Historic Other Non-Current Liabilities for Spyre Therapeutics (SYRE) over the last 8 years, with Sep 2025 value amounting to $3.2 million.

  • Spyre Therapeutics' Other Non-Current Liabilities fell 91.07% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 91.07%. This contributed to the annual value of $36.6 million for FY2024, which is 11.35% down from last year.
  • Latest data reveals that Spyre Therapeutics reported Other Non-Current Liabilities of $3.2 million as of Q3 2025, which was down 80.41% from $16.5 million recorded in Q1 2025.
  • Over the past 5 years, Spyre Therapeutics' Other Non-Current Liabilities peaked at $194.2 million during Q2 2023, and registered a low of $8,000 during Q1 2022.
  • Its 3-year average for Other Non-Current Liabilities is $47.5 million, with a median of $36.6 million in 2024.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 795.65% in 2021, then crashed by 96.12% in 2022.
  • Quarterly analysis of 5 years shows Spyre Therapeutics' Other Non-Current Liabilities stood at $16,000 in 2021, then slumped by 96.12% to $8,000 in 2022, then reached $41.3 million in 2023, then declined by 11.35% to $36.6 million in 2024, then slumped by 91.07% to $3.2 million in 2025.
  • Its Other Non-Current Liabilities stands at $3.2 million for Q3 2025, versus $16.5 million for Q1 2025 and $36.6 million for Q4 2024.